Condition

Prostatic Cancer, Castration-Resistant

ClinicalTrials.gov condition label

Clinical trials6

Recruiting1

Common interventions14

Lead sponsors shown6

Clinical trials

6 shown

Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional ImagingNCT06276465 · 2024-10-07

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07047118 · 2025-07-03

ACTIVE_NOT_RECRUITING

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerNCT04381832 · 2020-07-07

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)NCT04157088 · 2019-12-17

Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate CancerNCT04141709 · 2019-12-01

ACTIVE_NOT_RECRUITING

Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)NCT02866916 · 2017-09-01

Common interventions

EnzalutamideDRUG2 AAA617DRUG1 Androgen deprivation therapyDRUG1 Darolutamide (Nubeqa, BAY1841788)DRUG1 Darolutamide 300 mgDRUG1 DocetaxelDRUG1 EtrumadenantDRUG1 JSB462DRUG1 local ablative radiotherapyRADIATION1 QuemliclustatDRUG1 SGDRUG1 Stereotactic body radiation therapyRADIATION1 SXL01DRUG1 ZimberelimabDRUG1

Leading sponsors

Arcus Biosciences, Inc.1 Bayer1 Institut Claudius Regaud1 Novartis Pharmaceuticals1 Technische Universität Dresden1 UNICANCER1

Trial status mix

ACTIVE_NOT_RECRUITING2

COMPLETED1

RECRUITING1

TERMINATED1

WITHDRAWN1

Phase mix

PHASE23

PHASE12

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.